Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMTI OTCMKTS:INVVY NASDAQ:PMVP NASDAQ:TBPH NASDAQ:ZEAL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMTIApplied Molecular Transport$0.26$0.24$0.13▼$0.84$10.87M2.28470,969 shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsPMVPPMV Pharmaceuticals$1.54+0.7%$1.41$0.81▼$1.84$81.08M1.51599,400 shs686,775 shsTBPHTheravance Biopharma$14.00-0.1%$13.98$7.90▼$15.15$705.56M-0.03300,245 shs219,495 shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMTIApplied Molecular Transport0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%0.00%PMVPPMV Pharmaceuticals+0.65%+6.94%+14.93%+6.94%-9.94%TBPHTheravance Biopharma-0.07%+0.72%-0.50%+25.79%+59.09%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMTIApplied Molecular Transport$0.26$0.24$0.13▼$0.84$10.87M2.28470,969 shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsPMVPPMV Pharmaceuticals$1.54+0.7%$1.41$0.81▼$1.84$81.08M1.51599,400 shs686,775 shsTBPHTheravance Biopharma$14.00-0.1%$13.98$7.90▼$15.15$705.56M-0.03300,245 shs219,495 shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMTIApplied Molecular Transport0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%0.00%PMVPPMV Pharmaceuticals+0.65%+6.94%+14.93%+6.94%-9.94%TBPHTheravance Biopharma-0.07%+0.72%-0.50%+25.79%+59.09%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMTIApplied Molecular Transport 0.00N/AN/AN/AINVVYIndivior 0.00N/AN/AN/APMVPPMV Pharmaceuticals 2.33Hold$5.50257.14% UpsideTBPHTheravance Biopharma 3.00Buy$23.0064.29% UpsideZEALZealand Pharma A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PMVP, AMTI, ZEAL, TBPH, and INVVY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025PMVPPMV PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TBPHTheravance BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025PMVPPMV PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TBPHTheravance BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/12/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/11/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMTIApplied Molecular TransportN/AN/AN/AN/A$1.56 per shareN/AINVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/ATBPHTheravance Biopharma$64.38M10.95N/AN/A$3.57 per share3.92ZEALZealand Pharma A/S$46.54M17.59N/AN/A$3.38 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMTIApplied Molecular Transport-$126.32M-$1.90N/AN/AN/AN/A-223.46%-126.91%N/AINVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/APMVPPMV Pharmaceuticals-$58.71M-$1.57N/AN/AN/AN/A-47.94%-43.82%11/6/2025 (Estimated)TBPHTheravance Biopharma-$56.42M$0.2458.3340.00N/A16.88%6.93%3.52%11/11/2025 (Estimated)ZEALZealand Pharma A/S-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/ALatest PMVP, AMTI, ZEAL, TBPH, and INVVY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025TBPHTheravance Biopharma-$0.03N/AN/AN/A$19.89 millionN/A11/6/2025Q3 2025PMVPPMV Pharmaceuticals-$0.40N/AN/AN/AN/AN/A8/7/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39-$0.41-$0.02-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMTIApplied Molecular TransportN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/AZEALZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMTIApplied Molecular TransportN/A4.994.99INVVYIndiviorN/AN/AN/APMVPPMV PharmaceuticalsN/A12.5212.52TBPHTheravance BiopharmaN/A6.706.70ZEALZealand Pharma A/S0.934.794.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMTIApplied Molecular Transport41.79%INVVYIndivior0.05%PMVPPMV Pharmaceuticals90.20%TBPHTheravance Biopharma99.10%ZEALZealand Pharma A/S1.73%Insider OwnershipCompanyInsider OwnershipAMTIApplied Molecular Transport15.90%INVVYIndiviorN/APMVPPMV Pharmaceuticals7.57%TBPHTheravance Biopharma6.90%ZEALZealand Pharma A/S2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMTIApplied Molecular Transport1341.34 million34.76 millionOptionableINVVYIndivior800137.88 millionN/ANot OptionablePMVPPMV Pharmaceuticals5052.99 million48.98 millionOptionableTBPHTheravance Biopharma11050.36 million46.89 millionOptionableZEALZealand Pharma A/S35546.54 million45.51 millionNot OptionablePMVP, AMTI, ZEAL, TBPH, and INVVY HeadlinesRecent News About These CompaniesFactbox-Pharma companies announce direct-to-consumer sales and price cuts in USOctober 18, 2025 | msn.comNovo, Lilly's shares drop as Trump vows weight-loss drug price cutsOctober 18, 2025 | msn.comZealand Pharma (CPSE:ZEAL): Fresh Valuation Perspective Following Recent Share Price DeclineOctober 18, 2025 | finance.yahoo.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.October 17, 2025 | globenewswire.comNew Zealand's pharma growth complements ongoing FTA negotiations with India to boost pharma tradeOctober 10, 2025 | pharmabiz.comPBig pharma firms announce direct-to-consumer sales and price cuts in U.S.October 2, 2025 | reuters.comThe Top Big Pharmas Have $1.2T in Stretch M&A Firepower AvailableOctober 1, 2025 | biospace.comBFactbox-Big pharma firms announce direct-to-consumer sales and price cuts in U.S.October 1, 2025 | msn.comPharma Stocks Vary Worldwide Following New Trump TariffsSeptember 26, 2025 | finance.yahoo.comZealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media RelationsSeptember 24, 2025 | globenewswire.comEuropean stocks end higher with monetary policy in focus; Zealand Pharma gains 8%September 19, 2025 | msn.comZealand Pharma increases its share capital as a result of the exercise of employee warrantsSeptember 11, 2025 | globenewswire.comSAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025September 11, 2025 | globenewswire.comZealand Pharma to participate in upcoming investor conferences in September 2025August 28, 2025 | globenewswire.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.August 20, 2025 | globenewswire.comQ2 2025 Zealand Pharma A/S Earnings Call TranscriptAugust 14, 2025 | gurufocus.comZealand Pharma Announces Financial Results for the First Half of 2025August 14, 2025 | globenewswire.comZealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial resultsAugust 7, 2025 | globenewswire.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.July 18, 2025 | markets.businessinsider.comZealand Pharma major shareholder announcement: Van Herk Investments B.V.July 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMVP, AMTI, ZEAL, TBPH, and INVVY Company DescriptionsApplied Molecular Transport NASDAQ:AMTIApplied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.Indivior OTCMKTS:INVVY$21.85 -0.40 (-1.82%) As of 06/9/2023Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.PMV Pharmaceuticals NASDAQ:PMVP$1.54 +0.01 (+0.65%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$1.53 -0.01 (-0.65%) As of 10/22/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Theravance Biopharma NASDAQ:TBPH$14.00 -0.01 (-0.07%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$13.99 -0.01 (-0.07%) As of 10/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Zealand Pharma A/S NASDAQ:ZEALZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
